The evolving role of advocacy in tuberculosis

The Lancet Respiratory Medicine

Volumn 2, Issue 4, 2014, Pages 258-259

  DeLuca, Andrea ^a   Lessem, Erica ^b   Wegener, Donna ^c   Mingote, Laia Ruiz ^d   Frick, Mike ^b   Von Delft, Dalene ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Treatment Action Group   (United States)

^c National Tuberculosis Controllers Association   (United States)

^d Planeta Salud   (Spain)

^e TB Proof   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; DELAMANID; RIFAPENTINE;

ACCESS TO INFORMATION; CLINICAL RESEARCH; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; EMPOWERMENT; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; MEDICAL DECISION MAKING; NOTE; OUTCOME ASSESSMENT; PATIENT ADVOCACY; PATIENT AUTONOMY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONALISM; PUBLIC HEALTH; QT PROLONGATION; STUDY DESIGN; TUBERCULOSIS; TUBERCULOSIS CONTROL; PROCEDURES; RESEARCH;

HUMANS; PUBLIC HEALTH; RESEARCH; TUBERCULOSIS;

EID: 84897963818     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70035-9     Document Type: Note

References (11)

1. Boulanger RF, Seidel S, Lessem E, et al. Engaging communities in tuberculosis research. Lancet Infect Dis 2013, 13:540-545.
2. Tameris M, Gelderbloem SJ, Rustomjee R An urgent call for a stronger, louder voice for TB vaccine advocacy. Tuberculosis 2013, 93:2777-2778.
3. Macq J, Torfoss T, Getahun H Patient empowerment in tuberculosis control: reflecting on past documented experiences. Trop Med Int Health 2007, 12:873-885.
4. Harrington M From HIV to tuberculosis and back again: a tale of activism in 2 pandemics. Clin Infect Dis 2010, 50:S260-S266.
5. Good participatory practice guidelines for TB drug trials Critical Path to TB Drug Initiatives, (accessed Jan 6, 2014). http://cptrinitiative.org/resources/gpp-tb-resource-document/.
6. Jindani A, Hatherill M, Charalambous S, et al. A multicentre randomized clinical trial to evaluate high-dose rifapentine with a quinolone for treatment of pulmonary TB: the RIFAQUIN trial. 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, GA, USA; Mar 3-6, 2013. 147LB.
7. Dorman S, Goldberg S, Feng P, et al. A dose-ranging study of daily rifapentine-containing regimens for intensive phase treatment of pulmonary TB: Tuberculosis Trials Consortium Study 29x. 44th Union World Conference on Lung Health; Paris, France; Nov 2, 2013. OP-230-02.
8. Deluca A, Lessem E, Wegener D, et al. Understanding barriers to rifapentine use in US tuberculosis programs to inform pricing advocacy. 18th Annual Conference of the Union-North America Region; Boston, MA, USA; Feb 28, 2014. F3.
9. Baussano I, Nunn P, Williams B, et al. Tuberculosis among health care workers. Emerg Infect Dis 2011, 17:488-494.
10. O'Donnell M, Jarand J, Loveday M High incidence of hospital admissions with multidrug resistant and extensively drug resistant tuberculosis among South African health care workers. Ann Intern Med 2010, 153:516-522.
11. Global strategy and targets for tuberculosis prevention, care and control after 2015 2014, World Health Assembly Executive Board, World Health Organization, Geneva.